Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL372577 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL372574 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL372480 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL28575943 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL2460192 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL372478 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL372195 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL163778 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL23012792 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL8845344 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118891028-A | Oral care compositions, methods and kits | 舒万诺知识产权公司 | 2024-11-01 | — | — | CN | claimed |
| US-20190216814-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2019-07-18 | — | — | US | claimed |
| CN-109414442-A | (S) liquid preparation of-N- (5- ((R) -2- (2,5- difluorophenyl)-pyrrolidin-1-yl)-pyrazolo [1,5-A] pyrimidin-3-yl) -3- hydroxyl pyrrolidine -1- formamide | 洛克索肿瘤学股份有限公司 | 2019-03-01 | — | — | CN | claimed |
| EP-3439662-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | Loxo Oncology Inc. (US) | 2019-02-13 | — | — | EP | claimed |
| EP-3439663-A1 | METHODS OF TREATING PEDIATRIC CANCERS | Loxo Oncology Inc. (US) | 2019-02-13 | — | — | EP | claimed |
| CN-109310694-A | METHODS OF TREATING PEDIATRIC CANCERS | 洛克索肿瘤学股份有限公司 | 2019-02-05 | — | — | CN | claimed |
| US-10137127-B2 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | LOXO ONCOLOGY, INC. (US) | 2018-11-27 | — | — | US | claimed |
| US-20170296544-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2017-10-19 | — | — | US | claimed |
| WO-2017176744-A1 | METHODS OF TREATING PEDIATRIC CANCERS | LOXO ONCOLOGY, INC. (US) | 2017-10-12 | — | — | WO | claimed |
| WO-2017176751-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | LOXO ONCOLOGY, INC. (US) | 2017-10-12 | — | — | WO | claimed |
| CN-101172104-A | Processes of making and using pharmaceutical formulations of antineoplastic agents | SCHERING CORP (US) | 2008-05-07 | — | — | CN | claimed |
| CN-100346784-C | pharmaceutical formulations of antineoplastic agents, in particular temozolomide, preparation method and use thereof | SCHERING CORP (US) | 2007-11-07 | — | — | CN | claimed |
| EP-1838307-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2007-10-03 | — | — | EP | claimed |
| WO-2006060464-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060122162-A1 | Methods of using temozolomide formulation intrathecally in the treatment of cancers | SCHERING CORPORATION | 2006-06-08 | — | — | US | claimed |
| US-6987108-B2 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION (US) | 2006-01-17 | — | — | US | claimed |
| CN-1635871-A | pharmaceutical formulations of antineoplastic agents, in particular temozolomide, preparation method and use thereof | SCHERING CORP (US) | 2005-07-06 | — | — | CN | claimed |
| EP-1478339-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2004-11-24 | — | — | EP | claimed |
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION | 2004-03-04 | — | — | US | claimed |
| WO-2003072082-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2003-09-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216814-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | IL5, IL1A, RRP15 | CA4 4402/4885ALDH1A1 1446/4885CASP1 173/4885 |
| US-10137127-B2 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | IL5, IL1A, RRP15 | CA4 4402/4885ALDH1A1 1446/4885CASP1 173/4885 |
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | ASNS, TP53, QPCTL | CA4 2466/4885ALDH1A1 3247/4885CASP1 2019/4885 |
| US-20170296544-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | IL5, IL1A, RRP15 | CA4 4402/4885ALDH1A1 1446/4885CASP1 173/4885 |
| US-20060122162-A1 | Methods of using temozolomide formulation intrathecally in the treatment of cancers | PMP22, TUBB2A, TUBB6 | CA4 678/4885ALDH1A1 1296/4885CASP1 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.